Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
This international study looked at the COVID vaccine and if it was safe for people with rheumatic conditions like axial SpA. The results were reassuring and showed the safety levels were similar to those who did not have a rheumatic condition.
Will ‘the feeling of abandonment’ remain? Persisting impacts of the COVID-19 pandemic on rheumatology patients and clinicians
With already weakened healthcare systems further exposed by the pandemic, this survey aimed to assess if the trust in medical relationships would be impacted long term, and if there would be an improvement in the pattern of reduced patient healthcare-seeking and symptom reporting.
Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations
NASS teamed up with other patient organisations to look at the experiences of people with axial SpA; rheumatoid arthritis; Crohn’s Disease and ulcerative colitis; psoriasis and psoriatic arthritis when being switched to the biosimilar of the medication adalimumab.
Qualitative interview study exploring the patient experience of living with axial spondyloarthritis and fatigue: difficult, demanding and draining
NASS were pleased to fund this study looking at people’s experiences of fatigue and axial SpA.